| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5693766 | The Breast | 2017 | 5 Pages |
Abstract
This survey reflects the availability of HER2/neu testing and anti-HER2/neu therapy among physicians who participated in TEACH. A high proportion of women with HER2-overexpressing BC may not receive standard adjuvant therapy due to unavailability of the test and cost of therapy. Despite having some limitations, such as a possible selection bias of participating physicians, variable definitions of access to healthcare among respondents, and changes in trastuzumab availability since 2011, our results demonstrate that access to care and region of practice impact the implementation of cancer treatments.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Y. Chavarri-Guerra, J. St. Louis, A. Bukowski, E. Soto-Perez-de-Celis, P.E.R. Liedke, H. Symecko, B. Moy, M. Higgins, D.M. Finkelstein, P.E. Goss,